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SUMMARY
Objectives: The epilepsy treatment gap is largest in resource-poor countries.We eval-
uated the efficacy of a 1-day health education program in a rural area of Kenya. The pri-
mary outcome was adherence to antiepileptic drugs (AEDs) as measured by drug
levels in the blood, and the secondary outcomes were seizure frequency and Kilifi Epi-
lepsy Beliefs andAttitudes Scores (KEBAS).
Methods: Seven hundred thirty-eight people with epilepsy (PWE) and their designated
supporter were randomized to either the intervention (education) or nonintervention
group. Data were collected at baseline and 1 year after the education intervention was
administered to the intervention group. There were 581 PWE assessed at both time
points. At the end of the study, 105 PWE from the intervention group and 86 from the
nonintervention group gave blood samples, which were assayed for the most com-
monly used AEDs (phenobarbital, phenytoin, and carbamazepine). The proportions of
PWE with detectable AED levels were determined using a standard blood assay
method. The laboratory technicians conducting the assays were blinded to the ran-
domization. Secondary outcomes were evaluated using questionnaires administered
by trained field staff. Modified Poisson regression was used to investigate the factors
associated with improved adherence (transition from nonoptimal AED level in blood
at baseline to optimal levels at follow-up), reduced seizures, and improved KEBAS,
which was done as a post hoc analysis. This trial is registered in ISRCTN register under
ISRCTN35680481.
Results: There was no significant difference in adherence to AEDs based on detect-
able drug levels (odds ratio [OR] 1.46, 95% confidence interval [95% CI] 0.74–2.90,
p = 0.28) or by self-reports (OR 1.00, 95% CI 0.71–1.40, p = 1.00) between the inter-
vention and nonintervention group. The intervention group had significantly fewer
beliefs about traditional causes of epilepsy, cultural treatment, and negative stereo-
types than the nonintervention group. There was no difference in seizure frequency.
A comparison of the baseline and follow-up data showed a significant increase in
adherence—intervention group (36–81% [p < 0.001]) and nonintervention group
(38–74% [p < 0.001])—using detectable blood levels. The number of patients with
less frequent seizures (≤3 seizures in the last 3 months) increased in the interven-
tion group (62–80% [p = 0.002]) and in the nonintervention group (67–75%
[p = 0.04]). Improved therapeutic adherence (observed in both groups combined)
was positively associated with positive change in beliefs about risks of epilepsy (rela-
tive risk [RR] 2.00, 95% CI 1.03–3.95) and having nontraditional religious beliefs (RR
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2.01, 95% CI 1.01–3.99). Reduced seizure frequency was associated with improved
adherence (RR 1.72, 95% CI 1.19–2.47). Positive changes in KEBAS were associated
with having tertiary education as compared to none (RR 1.09, 95% CI 1.05–1.14).
Significance: Health education improves knowledge about epilepsy, but once only con-
tact does not improve adherence. However, sustained education may improve adher-
ence in future studies.
KEY WORDS: Epilepsy, Education intervention, Adherence, Beliefs about epilepsy,
Seizure frequency.
Epilepsy is most prevalent in low income countries
(LICs).1 It can be managed successfully, with >70% of peo-
ple with epilepsy (PWE) achieving full seizure control or
significant reduction in seizure frequency following effec-
tive use of antiepileptic drugs (AEDs).2 However, a signifi-
cant number of people with active epilepsy still do not
receive appropriate treatment, what is referred to as “the
epilepsy treatment gap” (ETG).3 In systematic reviews, the
ETG ranged from 31 to 100% in low and middle income
countries, with the highest ETGs being in rural areas and
LICs.2,4 The gap is influenced by limited knowledge of epi-
lepsy, cultural beliefs, untrained health workers, cost of
treatment, and unavailability of AEDs.2 Recently we
showed that cultural beliefs and lack of knowledge about
epilepsy are important risk factors for ETG and that adher-
ence may be improved by at least 20%, if beliefs could be
modified.5 Most PWE in LICs may only access specialist
services once in their lives.
Previous studies have suggested that health education
may encourage AEDs use.6,7 A randomized controlled trial
of the Modular Service Package Epilepsy (MOSES) in Eur-
ope found that patient education improved knowledge about
epilepsy, coping strategies, and seizure outcome, but this
study did not investigate improvement in adherence.8 Dem-
onstration projects in rural China improved biomedical care
using education and treatment interventions,9,10 but were
not tested with randomized controlled trials. The findings
from these two studies cannot be extrapolated to Africa due
to different sociocultural backgrounds and health systems.
We assessed the impact of a one-day low-cost
educational intervention on adherence to AEDs, seizure
frequency, and Kilifi Epilepsy Beliefs and Attitudes Scores
(KEBAS).
Methods
Study setting
The study was conducted in the Kilifi Health and Demo-
graphic Surveillance System (KHDSS), in which there were
261,919 residents in 2011.11 Most people are Giriama
(45%), and about 55% of the population is considered poor;
80% depend on subsistence farming. KHDSS is served by
one district level hospital, Kilifi District Hospital (KDH),
which stocks four AEDs: phenobarbital, phenytoin, carba-
mazepine, and sodium valproate. There are 13 health clinics
and dispensaries that stock only phenobarbital, although the
supply is erratic.
Study participants
This study is part of an epidemiologic survey of epilepsy
conducted in 2008, in which 738 people of all ages had
active convulsive epilepsy, defined as at least two unpro-
voked convulsions, with one in the 12 months prior to being
assessed.12 Recruitment of PWE involved in this study
started in August 2009.
Randomization andmasking
The data manager used computer-generated randomiza-
tion to allocate the 738 participants to either the intervention
or nonintervention group (Fig. 1). The laboratory techni-
cians conducting the assays were blinded to the randomiza-
tion. The questionnaires were administered by trained field
staff, both at baseline and follow-up.
Study design
The participants completed questionnaires immediately
before the educational intervention and 1 year after the edu-
cation intervention was implemented in the intervention
group (Fig. S1). The nonintervention group received the
health education after the second assessment. If the PWE
was a child or was cognitively impaired, the questionnaire
was administered to a caregiver.
Educational intervention
The educational intervention was only randomized in the
PWE and caregivers. In addition, discussions with tradi-
tional healers and sensitization of medical providers
occurred. The intervention was designed and delivered by a
team of epilepsy researchers and field staff who had a good
relationship with the community.
Educational intervention for PWE and caregivers
The PWE and an identified designated supporter (care-
giver) were invited to a one-day education program on epi-
lepsy, types of seizures, causes of epilepsy, effects of
epilepsy on child development, treatment of epilepsy, side
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effects of drugs, drug safety, what to do during a seizure,
when to take a PWE to hospital, prevention of epilepsy,
what PWE can and cannot do, and advice to families. The
intervention was tested as one contact, since most patients
in Africa may only be seen once a year at a center with spe-
cialists. Only one workshop was held per week. The inter-
vention took 5 months to deliver. The workshop consisted
of a maximum of 20 people, and a total of 19 workshops
were conducted. Techniques such as role-plays, picture
materials, group discussions, songs, and narratives from
PWE were used. The training was delivered in the partici-
pants’ native language (Kigiriama) and Kiswahili. A bro-
chure written in Kiswahili detailing all the topics discussed
was given to each participant. The workshops were sched-
uled with a clinic visit.
Discussions with traditional healers
Although the original design was to randomize the tradi-
tional healers consulted by the PWE, most traditional heal-
ers could neither be traced nor matched to PWE.
Consequently, 51 traditional healers were invited to a one-
day workshop in which the topics were similar to those dis-
cussed with the PWE.
Sensitization of medical providers
Fourteen health providers (nurses and clinical officers)
from public health facilities within KHDSS attended a one-
day workshop on epilepsy management. Topics discussed
included epidemiology of epilepsy, definition of epilepsy,
seizures and other terminologies, causes of epilepsy, com-
mon precipitating factors of epilepsy, international classifi-
cation of epileptic seizures, diagnosis of epilepsy,
differential diagnosis of epilepsy, conditions coexisting
with epilepsy, management of epilepsy, and clinical
clerking skills.
Outcomes
The primary outcome was improvement in adherence of
PWE to AEDs as measured by self-reports and drug levels
in the blood. Secondary outcomes were comparison of sei-
zure frequency, and KEBAS between the intervention and
nonintervention group. These primary and secondary mea-
sures were also compared between the baseline and end of
the study. Seizures were defined as less frequent if the
patients experienced ≤3 seizures in the last 3 months. In this
study, “reduced seizures” was defined as a reduction in sei-
zure frequency at the end of the study compared to baseline.
Measuring blood level adherence
Blood samples were assayed for the most commonly used
AEDs (phenobarbital, phenytoin, and carbamazepine).
Plasma drug concentrations were measured using a fluores-
cence polarization immunoassay analyser (TDxFLx Abbott
Laboratories, Abbott Park, IL, U.S.A.). The detectable
ranges for the different drugs were the following: phenobar-
bital 1.1 lg/mL, phenytoin 1.0 lg/mL, and carbamazepine
0.5 lg/mL.13 The optimal ranges were defined as follows:
phenobarbital 10–40 lg/mL, phenytoin 10–20 lg/mL, and
carbamazepine 4.0–12 lg/mL.14 An individual was defined
as adherent if AEDs were detectable in their blood, and
improved adherence if the AED levels were within the opti-
mal levels at follow-up. There were no obvious serious risks
in this study except for slight pain due to needle pricks for
which the PWEwere appropriately counseled.
Figure 1.
A flow chart representation of the
participant flow. Seven hundred
thirty-eight people with epilepsy
(PWE) were randomized, but analysis
was done for the 581 who were
observed at both the beginning
and end of the study. Assays of
antiepileptic drugs were done on
105 in the intervention and 86 in the
nonintervention group who
provided blood samples.
Epilepsia ILAE
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Questionnaires
The questionnaires for the study were developed in Eng-
lish, translated into the local language, and then back-trans-
lated. Questions were grouped into four categories:
sociodemographic characteristics (age, sex, religion, and
education), severity of epilepsy (frequency of seizures,
injury during a seizure, and number of medications [mono-
therapy or polytherapy]); adherence (details of taking pre-
scribed medication regimen); and questions on epilepsy
beliefs and attitudes.
PWEwere asked questions regarding the AEDs they were
currently taking and in addition requested to display them
on a board to aid recognition. Self-reported adherence was
assessed using a four-item Morisky medication adherence
scale that has been used in other epilepsy studies.5,15,16
Epilepsy beliefs and attitudes were measured using
KEBAS,17 which has 34 questions that constitute five sub-
scales (causes of epilepsy, biomedical treatment of epilepsy,
cultural treatment of epilepsy, risk and safety concerns, and
negative stereotypes about epilepsy). Higher scores
reflected more positive beliefs and attitudes about epilepsy.
Ethical considerations
Written informed consent was obtained from all study
participants or guardians. Approval for the study was
obtained from the Kenya Medical Research Institute
National Ethical Review Committee. This study is regis-
tered in ISRCTN register under ISRCTN35680481 and fol-
lows the consort guidelines.18 The full protocol can be
accessed from the KEMRI/Wellcome trust website http://
www.kemri-wellcome.org/projects/406.
Statistical analysis
An estimated sample size of 600 PWE with equal num-
bers in each group provided 99% power to detect a 20%
change in adherence to AEDs from 30% to 50%. Data were
double entered and verified in MySQL. All statistical analy-
ses were performed using STATA version 12 (STATA
Corp, College Station, TX, U.S.A.). We used Pearson’s chi-
square to compare the proportion of PWE adhering to AEDs
and with less frequent seizures between intervention and
nonintervention groups at the end of the study, and between
baseline and follow-up. In addition, logistic regression was
also used to compare the odds of adhering to AEDs at the
end of study between the intervention and nonintervention
groups. KEBAS between the groups were compared using t-
tests. Other quantitative variables were compared using t-
test, whereas Pearson chi-square was used for categorical
variables.
Following the improvement in adherence, in which 29 of
83 PWE transit from nonoptimal AED levels at baseline to
optimal levels at follow-up, we did a post hoc analysis of the
factors that could be associated with that improvement.
Similarly, this was done for 347 PWE who had changes in
seizure frequency, of whom 244 had a reduction in seizures,
and for changes in KEBAS where 534 of 581 had a positive
change in scores. In this analysis, improvement in KEBAS
was defined as an improvement in scores in at least one of
the items of KEBAS. Demographic factors included in the
analyses were age, sex, religious affiliation, and education
level. On the other hand, epilepsy-related variables included
learning difficulties, neurologic deficits, number of medica-
tions (monotherapy or polytherapy), and whether one had
injuries. Modified Poisson regression was used to ascertain
relative risks, which unlike the odds ratios do not overesti-
mate the effect size when the rare event assumption is vio-
lated.19 Relative risks are preferred over odd ratios in most
prospective studies.20,21 These analyses were adjusted for
the intervention because they were done for the two groups
combined. We first examined univariate associations and
the variables with p-values < 0.25 were retained in the final
multivariable models to identify the independent associa-
tions. p-Values < 0.05 were considered statistically signifi-
cant.
Results
Study participants
Data were analyzed for 581 PWE observed at both time
points. At baseline, the two groups had similar social demo-
graphic and clinical characteristics (Table 1). In the 157
PWE not seen after 1 year (because of death [45.2%], out-
migration [48.4%], and withdrawal [5.7%] [Fig. 1]), there
were no statistically significant differences in demographic
and epilepsy-related characteristics between the groups. A
significantly higher proportion of those not seen after one
year had more cognitive impairment, learning difficulties,
and were on polytherapy compared to the 581 who were
seen.
At the end of the study, only 105 PWE from the interven-
tion group and 86 from the nonintervention groups gave
blood samples. In both groups combined, phenobarbital was
detected in 84, phenytoin in 58, and carbamazepine in 75.
Ninety-three people (48.7%) had optimal drug levels, 62 on
phenobarbital, 3 on phenytoin, 24 on carbamazepine, and 2
on both phenobarbital and carbamazepine. In comparison to
those that gave blood samples, those who did not give sam-
ples held significantly more traditional religious and cul-
tural beliefs, and believed that AEDs caused epilepsy. The
self-reported adherence had low sensitivity (46.2%, 95% CI
35.8–56.9%) and specificity (40.8%, 31–51.2%) compared
to adherence based on optimal levels. Similarly the sensitiv-
ity (46.3%, 38.1–54.7%) and specificity (23.8%, 72.1–
39.5%) were low based on detectable levels.
Outcomes at follow-up: comparison of intervention and
nonintervention groups
There was no significant difference in the adherence to
AEDs based on self-reports (OR 1.00, 95% CI 0.71–1.40,
p = 1.00), detectable (OR 1.46, 95% CI 0.74–2.90,
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p = 0.28), and optimal (OR 0.91, 95% CI 0.51–1.61,
p = 0.74) drug levels, between the two groups (Table 2). In
addition, there was no statistically significant difference in
mean blood concentrations of AEDs between the groups.
PWE in the intervention group had higher scores than PWE
in the nonintervention group for beliefs about cultural treat-
ment (p = 0.001), lack of negative stereotypes (p = 0.001),
and beliefs about causes of epilepsy (p = 0.04) (Table 2).
Seizure frequency was not different between the groups.
Comparison of measures at baseline and follow-up
The proportion of PWE with therapeutic, detectable, or
self-reported adherence to AEDs increased at follow-up
from the baseline in both groups with larger increase
recorded in the intervention group (Table 3). In the inter-
vention group, the adherence (measured by detectable levels
of AEDs) improved from 36% to 81%, whereas the nonin-
tervention group improved from 38% to 74%. Furthermore,
there was a significant increase in proportion of PWE with
less frequent seizures at follow-up compared with those at
baseline in both groups; with larger increases in the inter-
vention group. Overall there was a significant improvement
in KEBAS scores for perceptions about PWE and reduction
in traditional beliefs of treatment. There was improvement
in KEBAS score for item on the perceptions of PWE at fol-
low-up compared to baseline for the nonintervention group
(10.0 at follow-up vs. 8.5 at baseline, p < 0.001). In the
intervention group, there was a significant reduction in the
beliefs about cultural treatment of epilepsy (12.8 at follow-
up vs. 11.0 at baseline, p < 0.001) and negative perceptions
of PWE (11.0 at follow-up vs. 8.4 at baseline, p < 0.001),
but not in KEBAS scores for the causes, biomedical treat-
ment, and risks of having epilepsy. For the nonintervention
group, there was no observed difference in KEBAS scores
for biomedical causes or treatment, traditional-treatment,
and risks of epilepsy (Table 3).
Factors associated with improved adherence
Univariate analysis of factors associated with improved
adherence, reduced seizures, and positive change in KEBAS
are shown in Tables 4, and Tables S1 and S2, respectively.
From the multivariable analysis, reduced seizure frequency
Table 1. Baseline demographic and clinical characteristics
Variable
Intervention group (N = 303)
Nonintervention group
(N = 278)
p-Valuen % n %
Age: Mean (SD) 303 19.2 (17.4) 278 19.5 (15.6) 0.86
Female 143 47.2 138 49.6 0.56
Religion
Traditional 127 41.9 128 46.0
Christian 136 44.9 122 43.9
Islam 40 13.2 28 10.1 0.41
Education level
None 142 46.9 114 41.0
Primary 138 45.5 142 51.1
Secondary 17 5.6 20 7.1
Tertiary 6 2.0 2 0.7 0.23
Learning difficulties 96 31.9 85 30.6 0.77
Neurologic deficits 70 23.1 54 19.4 0.28
On polytherapy 54/154 35.1 57/154 370 0.72
Seizure frequency (last 3 months)
None 96 31.9 91 32.7
1–3 91 30.0 95 34.2
4–6 45 14.9 34 12.2
>6 71 23.4 58 20.9 0.58
Adherence
Self-reported 52/195 26.7 54/199 27.1
Blood levels, detectable 71/195 36.4 76/199 38.2
Blood levels, optimal 52192 27.1 59/196 30.1
KEBAS n Mean (SD) n Mean (SD) p-Value
Beliefs about causes of epilepsy 303 7.3 (2.8) 278 7.3 (2.9) 0.82
Beliefs about biomedical treatment 303 15.0 (2.0) 278 14.9 (2.2) 0.63
Beliefs about cultural treatment 303 11.0 (4.8) 278 11.1 (4.9) 0.79
Beliefs about risks of epilepsy 303 7.4 (1.3) 278 7.5 (1.2) 0.41
Stereotypes about epilepsy 303 8.4 (4.2) 278 8.5 (4.6) 0.72
If all the data were not available, both the numerators and denominators are provided.
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was associated with improved adherence based on optimal
blood concentrations of AEDs (relative risk [RR] 1.72, 95%
CI 1.19–2.47), but not with age (p = 0.11), sex (p = 0.08),
and being injured (p = 0.36). Improved adherence was posi-
tively associated with positive change in beliefs about risks
of epilepsy (RR 2.00, 95% CI 1.03–3.95) and having nontra-
ditional religious beliefs (RR 2.01, 95% CI 1.01–3.99), but
not with age, neurologic deficits, and stereotypes about
epilepsy (Table 5). Positive changes in KEBAS were asso-
ciated with having tertiary education as compared to none
(RR = 1.09, 1.05–1.14), but being injured (p = 0.088) and
having less frequent seizures (p = 0.245) were not signifi-
cantly associated with KEBAS.
Discussion
This study tested the efficacy of a one-day educational
intervention to improve adherence to AEDs in a resource-
poor setting, where the treatment gap was moderately high
(62%).5 We found no difference in adherence between the
intervention and nonintervention groups after the interven-
tion was implemented, but adherence was improved in both
groups, and this improvement was associated with reduced
seizure frequency. Compared with the nonintervention
group, the intervention group was associated with improve-
ments in knowledge about causes of epilepsy, fewer beliefs
in negative stereotypes, and cultural/traditional treatment.
Increase in knowledge about the risks associated with epi-
lepsy and having nontraditional religious beliefs were
important predictors of improved adherence in both groups
combined.
Adherence and education intervention
This study did not find any significant improvements in
adherence between the intervention and nonintervention
groups following the education intervention, although there
was a >20% improvement in both groups combined as mea-
sured by AEDs in the blood. This lack of difference in
adherence between the groups may have a number of expla-
nations. First, the improvement in adherence may have been
related to factors other than the intervention, for example,
limited access and supply of AEDs. Secondly, the follow-up
period may have been too short.22 Lastly, and most likely,
the improved adherence in both groups could be explained
by the sharing of knowledge between the groups.23 Such an
occurrence may be prevented by using a cluster-randomized
design.24 Contamination could be caused by health workers
and traditional healers while they attended to the patients in
the nonintervention group. This could also have underesti-
mated the difference in KEBAS between the two groups.
Comparison of adherence between baseline and follow-
up
Despite the lack of significant improvement in adherence
between the intervention and nonintervention groups, there
was an overall significant absolute improvement (>34%) in
Table 2. Comparison of outcomes between the intervention and nonintervention groups at the end of the study
Variable
Intervention group (n = 303)
Nonintervention group
(n = 278)
p-Valuen % n %
Adherence
Self-reported 193 63.7 177 63.7 1.00
Detectable level in blood 85/105 81.0 64/86 74.4 0.28
Optimal level in blood 50/105 47.6 43/86 50.0 0.74
AED levels in blood: mean level (SD)
Phenobarbital 63 13.1 (11.9) 53 11.3 (10.8) 0.35
Phenytoin 46 2.1 (2.2) 41 2.4 (3.8) 0.70
Carbamazepine 34 3.3 (4.3) 48 3.7 (3.9) 0.66
Seizures
Less frequent seizures 243 80.2 208 74.8 0.12
Seizure frequency (last 3 months)
None 154 50.8 130 46.8
1–3 89 29.4 78 28.1
4–6 26 8.6 26 9.4
>6 34 11.2 44 15.8 0.40
KEBAS n Mean (SD) N Mean (SD) p-Value
Beliefs about causes of epilepsy 303 7.4 (2.6) 278 7.0 (2.7) 0.04
Beliefs about biomedical treatment 303 15.1 (15.1) 278 15.0 (1.9) 0.57
Beliefs about cultural treatment 303 12.8 (4.1) 278 11.6 (4.3) <0.001
Beliefs about risks of epilepsy 303 7.3 (1.3) 278 7.4 (1.4) 0.27
Stereotypes about epilepsy 303 11.0 (3.8) 278 10.0 (3.9) <0.001
If all the data were not available, both the numerator and denominators are provided. % column records percentage of those observed with the characteristic
under consideration except for the items of KEBAS and levels of AEDs in blood where we have the mean (standard deviation) of the scores.
Epilepsia, 55(2):344–352, 2014
doi: 10.1111/epi.12498
349
Evaluation of Kilifi Epilepsy Education Programme
adherence at follow-up compared with baseline in both
groups, suggesting that factors other than the intervention
may have caused the improvement in adherence that was
observed. These factors may also explain significant reduc-
tion in seizure frequency with increased utilization of AEDs
and higher levels for AEDs. In other studies, reduction in
seizure frequency is associated with improved adherence to
AEDs, which may be related to multiple factors.8,25 Many
other studies have explored usefulness of interventions by
comparing baseline and follow-up measures only,26–28
although the results would be more reliable with a compari-
son group in a randomized controlled trial design.29 How-
ever, these improvements in both groups should be
interpreted cautiously as they may be related to other fac-
tors, for example, sensitization of the community and the
placebo effect.
Beliefs about epilepsy and adherence
There was improvement in KEBAS, but this may not
have directly resulted in improved adherence. Even though
negative beliefs about epilepsy influence adherence for
PWE,2,5 this study demonstrates that the resulting improve-
ment may not always translate into improvement in adher-
ence. This inconsistency may be explained in two ways.
First, a longer period of follow-up may be needed for an
effect on adherence to be seen. This Hawthorne effect may
remain even after the conclusion of a study resulting in con-
comitant change in adherence.30 The change in beliefs about
epilepsy in this study is in a direction associated with
improved adherence in other studies.31,32 Secondly, other
different interventions such as reminders about prescrip-
tions33 and improving access to AEDs may be required to
change adherence. There is need to apply further
interventions, since ETG is still high in the area, although it
was lowered from 70.3% in 2003 to 62.4% in 2010.5,34
Factors associated with changes in the outcomes
Improved therapeutic adherence was positively correlated
with being a nontraditionalist and positive changes in risks
of epilepsy, possibly because these patients were more likely
to believe in and seek biomedical treatment. Improvement in
KEBAS was associated with being educated, perhaps
because of the improved level of understanding in these peo-
ple. These conclusions show that improvement in adherence
depends on several factors but not only on education.
Strengths and limitations
This is the first trial to test the usefulness of an educa-
tional intervention to reduce the ETG in a resource-poor set-
ting. The groups were selected randomly, ensuring
similarities between the two groups to avoid any bias in the
outcome. The outcome was measured with validated tools
that were developed for use in this setting. The limitations
of this study are the following: the intervention was
advanced only once, inability to prevent spread of
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knowledge by health care workers, traditional healers and
participants in the intervention group to those in the non-
intervention group, the duration of follow-up was relatively
short and therefore the full effect of the education interven-
tion may not have been apparent. In addition, the majority
of the study participants did not give blood.
Conclusion
Health education improves knowledge about epilepsy,
but once only contact does not improve adherence. How-
ever, sustained education may in part improve adherence in
future studies. The findings of this study are useful in plan-
ning interventions aimed at reducing the treatment gap in
other similar settings in Africa and across the world.
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Table 4. Univariate analysis for factors associated with improved therapeutic adherence adjusted for the intervention
Variable Improved (n = 29) No Improvement (n = 54) RR (95%CI) p- Value
Age: Mean (SD) 29.4 (17.8) 22.1 (13.6) 1.02 (1.00–1.03) 0.01
Sex
Female 15 (51.7%) 24 (44.4%) 1
Male 14 (48.3%) 30 (55.6%) 0.79 (0.44–1.43) 0.44
Injured
No 17 (58.6%) 32 (59.3%) 1
Yes 12 (41.4%) 22 (40.7%) 1.01 (0.56–1.84) 0.97
Educational level
None 11 (37.9%) 21 (38.9%) 1
Primary 16 (55.2%) 31 (57.4%) 0.97 (0.52–1.79) 0.91
Secondary 2 (6.9) 2 (3.7%) 1.60 (0.47–5.44) 0.46
Religion
Traditional 7 (21.2%) 26 (44.0%) 1
Nontraditional 22 (78.8%) 28 (56.0%) 2.10 (1.00–44.40) 0.05
Learning difficulties
No 25 (86.2%) 43 (76.6%) 1
Yes 4 (13.8%) 11 (20.4%) 0.71 (0.28–1.82) 0.48
Neurologic deficit
No 24 (82.8%) 49 (90.7%) 1
Yes 5 (17.2%) 5 (9.3%) 1.59 (0.81–3.11) 0.18
On polytherapy 6/18 (33.3%) 13/34 (38.2%) 0.82 (0.36–1.89) 0.65
Improved KEBAS: Mean (SD)
Beliefs about causes of epilepsy 6 (20.7) 16 (29.6) 0.75 (0.35–1.61) 0.46
Beliefs about biomedical treatment 10 (34.5) 20 (37.0) 0.98 (0.53–1.83) 0.95
Beliefs about cultural treatment 8 (27.6) 7 (13.0) 1.02 (0.57–1.85) 0.94
Beliefs about risks of epilepsy 15 (51.7) 27 (50.0) 1.89 (1.04–3.45) 0.04
Stereotypes about epilepsy 22 (75.9) 30 (55.6) 1.86 (0.90–3.87) 0.10
Data are number of patients (%) except for items of KEBAS and age where we have the mean (standard deviation) of the scores. This analysis was done on 83
PWEwho had nonoptimal levels of AEDs in the blood at baseline and had optimal levels of AEDs in blood at follow-up.
Table 5. Multivariable analysis for factors associated
improved adherence based on therapeutic levels
adjusted for the intervention
Variable RR (95%CI) p-Value
Age 2.10 (0.94–4.69) 0.07
Religion
Traditional 1
Nontraditional 2.01 (1.01–3.99) 0.05
Improved KEBAS
Beliefs about risks of epilepsy 2.00 (1.01–3.95) 0.04
Stereotypes about epilepsy 1.98 (0.94–4.17) 0.07
Neurologic deficit
No 1
Yes 1.29 (0.51–3.26) 0.59
Nontraditional religious beliefs refer to Christianity and Islam.
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